Inclusion Criteria:

- Histologically or cytologically proven squamous cell carcinoma of th head and neck or
its variants. Primary tumor sites eligible include nasopharynx, oral cavity,
oropharynx, hypopharynx, larynx, or unknown primary SSCHN. Although they have
squamous histology, tumors of the skin, nasal cavity and paranasal sinuses are
excluded because their responsiveness to chemotherapy and radiotherapy may differ.

- Stage III or IV disease, without evidence of distant metastasis, according to the
American Joint Committee on Cancer.

- Measurable disease, according to RECIST.

- Treatment-naive SSCHN, i.e. no prior chemotherapy, radiotherapy or attempted complete
resection.

- < CTCAE v3.0 Grade 2 neuropathy

- 18 years of age or older

- ECOG Performance Status of 0 or 1

- No active alcohol addiction or other condition that, in the opinion of the study
investigators, would interfere with the subject's ability to comply with the
treatment plan.

- Lab values as outlined in the protocol

- Negative pregnancy test within 7 days of study entry

Exclusion Criteria:

- Pregnant or breast-feeding women, or women and men of childbearing potential not
willing to use adequate contraception while receiving treatment and for at least 6
months thereafter.

- Symptomatic peripheral neuropathy Grade 2 or greater by CTCAE v3.0

- History of other malignancy within the previous 5 years, except for non-melanoma skin
cancer, carcinoma in situ of the cervix, bladder or head and neck.

- Prior therapeutic radiation to the head and neck

- Other serious illness or medical conditions, including but not limited to: unstable
cardiac disease or myocardial infarction within 6 months prior to study entry;
history of significant neurologic disorder, including advanced dementia or
uncontrolled seizure disorder; clinically significant uncontrolled infection; active
peptic ulcer disease defined as unhealed or clinically active ulcer; hypercalcemia;
active drug addiction including cocaine or intravenous drug use, defined as occuring
within 6 months preceding diagnosis; chronic obstructive pulmonary disease;
autoimmune disease requiring active therapy; severe psoriasis; chronic uncontrolled
diarrhea.

- Patients who experienced involuntary weight loss of more than 20% of their body
weight in the two months preceding study entry

- Concurrent treatment with any other anticancer therapy

- Prior therapy that targets the EGFR pathway

- Participation in an investigational drug trial within 30 days of study entry